Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Preferred Stock Liabilities (2020)

Design Therapeutics' Preferred Stock Liabilities history spans 1 years, with the latest figure at $45.4 million for Q4 2020.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $45.4 million in Q4 2020 year-over-year; TTM through Dec 2020 was $45.4 million, a N/A change, with the full-year FY2020 number at $45.4 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $45.4 million in Q4 2020 for Design Therapeutics, roughly flat from $45.4 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for DSGN hit a ceiling of $45.4 million in Q1 2020 and a floor of $45.4 million in Q1 2020.